EPA bans asbestos, a deadly carcinogen still in use decades after partial ban
WASHINGTON — The Environmental Protection Agency on Monday announced a comprehensive ban on asbestos, a…
Author: STAT
Contineum Therapeutics files for IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
I was wrong about Geron. For years, I’ve believed — and declared publicly — that…
STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
The harms of adverse childhood experiences are well-known. But positive experiences can affect future health, too
I was recently working with a young mother who struggled with depression and anxiety in…
STAT+: As AI marches into medicine, investors eye security, privacy startups
Investors are starting to back startups that offer privacy and security services to bolster health…
STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them…
STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty
Around this time three years ago, while most of us navigated pandemic life, real estate developers…
The latest twist in John Green’s anti-tuberculosis story: working with governments
WASHINGTON — John Green, the popular novelist and YouTube star, gave the health care world…
STAT+: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns
A panel of expert advisers to the Food and Drug Administration on Friday voted in…
Q&A: Is it time for scientists to rethink how they study sex in research?
Our understanding of sex has come a long way. Aristotle theorized that heat during conception…
STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more
And so, another working week will soon come to a close. Not a moment too…
What happens when an approved drug doesn’t work?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Lessons for scientists from the All of Us Research Program backlash
Scientists are taught early in our training that criticism is a fundamental part of the…
STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and…
What the brains of song birds can teach us about human stuttering
A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist…
.jpg)
Inside a push to create an NIH office for post-infection chronic illness
When the White House released President Biden’s 2025 budget requests this week, funding for biomedical…
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And…
STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat…
Senators press HHS secretary on Change HealthCare cyberattack fallout
WASHINGTON— Senators want answers from the Biden administration on the recent cyberattack that froze millions…
Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan
A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan…
STAT+: EPA restricts cancer-causing chemical used to sterilize medical devices
On Thursday, the Environmental Protection Agency finalized limits on a carcinogenic gas called ethylene oxide…
Virtual Event: March of the Biosimilars
Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET….
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.
LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based…
STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal…
Opinion: Prescription for resilience: Health care needs financial sector-inspired regulation
In the early days after it was hit by a cyberattack on Feb. 21, Change…
STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug…
STAT+: Q&A: Amid AI frenzy in medicine, a federal regulator’s quest to create safeguards
Micky Tripathi is equal parts excited — and deeply concerned — about the technological change…
STAT+: Argenx readies another blockbuster opportunity with its antibody drug
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China
WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese…
STAT+: RaDonda Vaught, former Vanderbilt nurse who accidentally killed patient, says hospital issues contributed, too
Speaking before a virtual audience of CommonSpirit Health employees, RaDonda Vaught, the former nurse who…
STAT+: Small studies offer hope CAR-T can fight an aggressive brain cancer
A series of new studies are raising hopes that CAR-T, a process in which treatments…
STAT+: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages
Doctors have been eagerly waiting for data on Guardant Health’s new blood-based colorectal cancer screening…
STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies
In a setback to the pharmaceutical industry, a U.S. appeals court has upheld an Arkansas…
STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Geron’s resurgence might have been short-lived
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Good health care price transparency rules are at risk if Congress doesn’t act
Consider shopping for cereal in the grocery store. Buyers easily know how many grams of…
STAT+: AI health care companies say they’ll keep humans in the loop. But what does that actually mean?
Developers of artificial intelligence models slowly making their way into medicine have long parried ethical…
STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his…
STAT+: “It’s a bit chaotic”: Hospitals struggle to validate AI-generated clinical summaries
Rob Bart remembers what it felt like, the moment of discovery. As an intern at…
After Amylyx ALS trial failure, patients share disappointment and fear — but some hope
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis…
STAT+: Here’s what you might have missed in Biden’s budget proposal
WASHINGTON — President Biden on Monday unveiled his requests for the 2025 budget, potentially his…
STAT+: For-profit health system’s Mass. hospitals teetering on the brink of financial disaster
Steward Health Care’s Massachusetts hospitals are on the brink of financial disaster. But in many…
Delta 8 THC use reported by 11% of high school seniors
WASHINGTON — In the last year, an estimated 11% of high school seniors have used…
STAT+: Researchers create talking throat patch for people with voice disorders
Researchers at the University of California, Los Angeles have built a soft, adhesive patch capable…
STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more
Top of the morning to you, and a fine one it is. Sunny skies and…
When did Wall Street sour on Lilly’s Alzheimer’s drug?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: No parent who has seen the children I’ve treated for measles would refuse a vaccine
Over the past year, I have watched many children die of measles. In the final…